We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $177M
1-Year Est. Return 91.13%
This Fund
S&P 500
This Quarter Est. Return
-2.38%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$85.4M
AUM Growth
–
Cap. Flow
+$87.1M
Cap. Flow %
102.07%
Top 10 Hldgs %
94.55%
Holding
13
New
13
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$19.1M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$14.3M
3
SCLN
Sciclone Pharmaceuticals Inc
SCLN
+$9.84M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$8.66M
5
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$7.51M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 91.37%
2 Miscellaneous 8.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VNDA icon
1
Vanda Pharmaceuticals
VNDA
$323M
$17.9M 20.93%
+1,918,929
New +$19.1M
CTIC
2
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$13.2M 15.42%
+1,069,862
New +$14.3M
SCLN
3
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
$10.8M 12.67%
+1,175,574
New +$9.84M
TBRA
4
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$8.38M 9.81%
+833,377
New +$8.66M
SGNT
5
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$7.36M 8.63%
+462,824
New +$7.29M
PTX
6
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$7.33M 8.59%
+248,465
New +$7.51M
FLNA
7
Filana Therapeutics
FLNA
$40M
$6.26M 7.33%
+510,714
New +$6.76M
FMI
8
DELISTED
Foundation Medicine, Inc.
FMI
$3.64M 4.27%
+173,049
New +$3.34M
VCEL icon
9
Vericel Corp
VCEL
$2.07B
$3.55M 4.16%
+1,376,887
New +$3.08M
ENTA icon
10
Enanta Pharmaceuticals
ENTA
$408M
$2.35M 2.75%
+71,147
New +$2.32M
DSCI
11
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$2.32M 2.72%
+507,799
New +$2.41M
CUTR
12
DELISTED
Cutera, Inc.
CUTR
$1.28M 1.5%
+100,000
New +$1.35M
SCTL
13
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$1.05M 1.23%
+130,345
New +$1.14M

Similar funds

RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
MSA
Marathon Strategic Advisors Pittsburgh, Pennsylvania $177M AUM 66.85% 1-Year Est. Return
HF
Holcombe Financial Atlanta, Georgia $177M AUM 13.35% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
CWP
Clark Wealth Partners O'fallon, Illinois $177M AUM 22.36% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
CMP
Christine Messmer PC Collegeville, Pennsylvania $177M AUM
JESC
J.E. Simmons & Co Dallas, Texas $177M AUM

Stonepine Capital Management's Q4 2015 Portfolio in Review

Q4 2015 is the first quarter with a 13F filing on record for Stonepine Capital Management, which disclosed 13 positions worth $85.4M. Its ten largest holdings account for 95% of the portfolio.

Its largest position is Vanda Pharmaceuticals: 1,918,929 shares worth $17.9M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, followed by Miscellaneous.

  • Stonepine Capital Management's largest Q4 2015 buy was Vanda Pharmaceuticals: 1,918,929 shares worth $17.9M.
  • Stonepine Capital Management's ten largest holdings make up 95% of its $85.4M portfolio in Q4 2015.
  • Stonepine Capital Management disclosed 13 positions in Q4 2015, its first 13F filing on record.

Based on Stonepine Capital Management's 13F filing for Q4 2015, filed 11 Feb 2016.